

### **AMENDMENT TO THE CLAIMS**

Please amend the claims as shown below without prejudice or disclaimer.

1-37 (Cancelled).

38. (New) An expression vector comprising a nucleic acid sequence CAP(6D)-1,2 as illustrated in SEQ ID NO.: 8 and Figure 9 or a fragment thereof and a nucleic acid sequence encoding human B7.1.
39. (New) The expression vector of claim 38 wherein the human B7.1 sequence is that illustrated in Figure 12.
40. (New) The expression vector of claim 38 or 39 wherein the vector is a plasmid or a viral vector.
41. (New) The expression vector of claim 40 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.
42. (New) The expression vector of claim 41 wherein the viral vector is a poxvirus selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
43. (New) The expression vector of claim 42 wherein the viral vector is a poxvirus selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
44. (New) The expression vector of claim 38 further comprising at least one additional tumor associated antigen.
45. (New) The expression vector of claim 38 further comprising at least one nucleic acid sequence encoding an angiogenesis-associated antigen.
46. (New) An isolated DNA molecule comprising the CEA(6D)-1,2 sequence illustrated in SEQ ID NO.: 8 and Figure 9 and a nucleotide sequence encoding human B7.1.
47. (New) The DNA sequence of claim 46 wherein the nucleotide sequence encoding human B7.1 is that illustrated in Figure 12.
48. (New) A method for preparing an expression vector comprising the nucleotide sequence CAP(6D)-1,2 as shown in SEQ ID NO.: 8 and Figure 9 and a nucleotide sequence comprising human B7.1, the method comprising recombining a plasmid having the sequence shown in Figure 12 into a first site of an ALVAC genome and recombining a plasmid having the sequence shown in Figure 13 into a second site of

the ALVAC genome.

49. (New) The method of claim 48 wherein either plasmid or the ALVAC genome further comprise at least one additional nucleotide sequence encoding a tumor associated antigen.
50. (New) The method of claim 48 wherein either plasmid or the ALVAC genome further comprise at least one additional nucleotide sequence encoding an angiogenesis-associated antigen.